2022-12-012023-11-302023-11-30false13735777JERICHO PHARMA LIMITED2024-06-03iso4217:GBPxbrli:pure137357772022-12-01137357772023-11-30137357772022-12-012023-11-30137357772021-11-10137357772022-11-30137357772021-11-102022-11-3013735777bus:SmallEntities2022-12-012023-11-3013735777bus:AuditExempt-NoAccountantsReport2022-12-012023-11-3013735777bus:FullAccounts2022-12-012023-11-3013735777bus:PrivateLimitedCompanyLtd2022-12-012023-11-3013735777core:WithinOneYear2023-11-3013735777core:AfterOneYear2023-11-3013735777core:WithinOneYear2022-11-3013735777core:AfterOneYear2022-11-3013735777core:ShareCapital2023-11-3013735777core:SharePremium2023-11-3013735777core:RevaluationReserve2023-11-3013735777core:OtherReservesSubtotal2023-11-3013735777core:RetainedEarningsAccumulatedLosses2023-11-3013735777core:ShareCapital2022-11-3013735777core:SharePremium2022-11-3013735777core:RevaluationReserve2022-11-3013735777core:OtherReservesSubtotal2022-11-3013735777core:RetainedEarningsAccumulatedLosses2022-11-3013735777core:LandBuildings2023-11-3013735777core:PlantMachinery2023-11-3013735777core:Vehicles2023-11-3013735777core:FurnitureFittings2023-11-3013735777core:OfficeEquipment2023-11-3013735777core:NetGoodwill2023-11-3013735777core:IntangibleAssetsOtherThanGoodwill2023-11-3013735777core:ListedExchangeTraded2023-11-3013735777core:UnlistedNon-exchangeTraded2023-11-3013735777core:LandBuildings2022-11-3013735777core:PlantMachinery2022-11-3013735777core:Vehicles2022-11-3013735777core:FurnitureFittings2022-11-3013735777core:OfficeEquipment2022-11-3013735777core:NetGoodwill2022-11-3013735777core:IntangibleAssetsOtherThanGoodwill2022-11-3013735777core:ListedExchangeTraded2022-11-3013735777core:UnlistedNon-exchangeTraded2022-11-3013735777core:LandBuildings2022-12-012023-11-3013735777core:PlantMachinery2022-12-012023-11-3013735777core:Vehicles2022-12-012023-11-3013735777core:FurnitureFittings2022-12-012023-11-3013735777core:OfficeEquipment2022-12-012023-11-3013735777core:NetGoodwill2022-12-012023-11-3013735777core:IntangibleAssetsOtherThanGoodwill2022-12-012023-11-3013735777core:ListedExchangeTraded2022-12-012023-11-3013735777core:UnlistedNon-exchangeTraded2022-12-012023-11-3013735777core:MoreThanFiveYears2022-12-012023-11-3013735777core:Non-currentFinancialInstruments2023-11-3013735777core:Non-currentFinancialInstruments2022-11-3013735777dpl:CostSales2022-12-012023-11-3013735777dpl:DistributionCosts2022-12-012023-11-3013735777core:LandBuildings2022-12-012023-11-3013735777core:PlantMachinery2022-12-012023-11-3013735777core:Vehicles2022-12-012023-11-3013735777core:FurnitureFittings2022-12-012023-11-3013735777core:OfficeEquipment2022-12-012023-11-3013735777dpl:AdministrativeExpenses2022-12-012023-11-3013735777core:NetGoodwill2022-12-012023-11-3013735777core:IntangibleAssetsOtherThanGoodwill2022-12-012023-11-3013735777dpl:GroupUndertakings2022-12-012023-11-3013735777dpl:ParticipatingInterests2022-12-012023-11-3013735777dpl:GroupUndertakingscore:ListedExchangeTraded2022-12-012023-11-3013735777core:ListedExchangeTraded2022-12-012023-11-3013735777dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-12-012023-11-3013735777core:UnlistedNon-exchangeTraded2022-12-012023-11-3013735777dpl:CostSales2021-11-102022-11-3013735777dpl:DistributionCosts2021-11-102022-11-3013735777core:LandBuildings2021-11-102022-11-3013735777core:PlantMachinery2021-11-102022-11-3013735777core:Vehicles2021-11-102022-11-3013735777core:FurnitureFittings2021-11-102022-11-3013735777core:OfficeEquipment2021-11-102022-11-3013735777dpl:AdministrativeExpenses2021-11-102022-11-3013735777core:NetGoodwill2021-11-102022-11-3013735777core:IntangibleAssetsOtherThanGoodwill2021-11-102022-11-3013735777dpl:GroupUndertakings2021-11-102022-11-3013735777dpl:ParticipatingInterests2021-11-102022-11-3013735777dpl:GroupUndertakingscore:ListedExchangeTraded2021-11-102022-11-3013735777core:ListedExchangeTraded2021-11-102022-11-3013735777dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-11-102022-11-3013735777core:UnlistedNon-exchangeTraded2021-11-102022-11-3013735777core:NetGoodwill2023-11-3013735777core:IntangibleAssetsOtherThanGoodwill2023-11-3013735777core:LandBuildings2023-11-3013735777core:PlantMachinery2023-11-3013735777core:Vehicles2023-11-3013735777core:FurnitureFittings2023-11-3013735777core:OfficeEquipment2023-11-3013735777core:AfterOneYear2023-11-3013735777core:WithinOneYear2023-11-3013735777core:ListedExchangeTraded2023-11-3013735777core:UnlistedNon-exchangeTraded2023-11-3013735777core:ShareCapital2023-11-3013735777core:SharePremium2023-11-3013735777core:RevaluationReserve2023-11-3013735777core:OtherReservesSubtotal2023-11-3013735777core:RetainedEarningsAccumulatedLosses2023-11-3013735777core:NetGoodwill2022-11-3013735777core:IntangibleAssetsOtherThanGoodwill2022-11-3013735777core:LandBuildings2022-11-3013735777core:PlantMachinery2022-11-3013735777core:Vehicles2022-11-3013735777core:FurnitureFittings2022-11-3013735777core:OfficeEquipment2022-11-3013735777core:AfterOneYear2022-11-3013735777core:WithinOneYear2022-11-3013735777core:ListedExchangeTraded2022-11-3013735777core:UnlistedNon-exchangeTraded2022-11-3013735777core:ShareCapital2022-11-3013735777core:SharePremium2022-11-3013735777core:RevaluationReserve2022-11-3013735777core:OtherReservesSubtotal2022-11-3013735777core:RetainedEarningsAccumulatedLosses2022-11-3013735777core:NetGoodwill2021-11-1013735777core:IntangibleAssetsOtherThanGoodwill2021-11-1013735777core:LandBuildings2021-11-1013735777core:PlantMachinery2021-11-1013735777core:Vehicles2021-11-1013735777core:FurnitureFittings2021-11-1013735777core:OfficeEquipment2021-11-1013735777core:AfterOneYear2021-11-1013735777core:WithinOneYear2021-11-1013735777core:ListedExchangeTraded2021-11-1013735777core:UnlistedNon-exchangeTraded2021-11-1013735777core:ShareCapital2021-11-1013735777core:SharePremium2021-11-1013735777core:RevaluationReserve2021-11-1013735777core:OtherReservesSubtotal2021-11-1013735777core:RetainedEarningsAccumulatedLosses2021-11-1013735777core:AfterOneYear2022-12-012023-11-3013735777core:WithinOneYear2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:CostValuation2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-012023-11-3013735777core:Non-currentFinancialInstrumentscore:CostValuation2023-11-3013735777core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-11-3013735777core:Non-currentFinancialInstrumentscore:CostValuation2022-11-3013735777core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-11-3013735777core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-11-3013735777bus:Director12022-12-012023-11-3013735777bus:Director22022-12-012023-11-3013735777bus:Director32022-12-012023-11-3013735777core:FurnitureFittingsToolsEquipment2022-11-3013735777core:FurnitureFittingsToolsEquipment2022-12-012023-11-3013735777core:FurnitureFittingsToolsEquipment2023-11-30

JERICHO PHARMA LIMITED

Registered Number
13735777
(England and Wales)

Unaudited Financial Statements for the Year ended
30 November 2023

JERICHO PHARMA LIMITED
Company Information
for the year from 1 December 2022 to 30 November 2023

Directors

FAHIM, Mohammed
PATEL, Vimal
SHARIF, Zahoor Ahmed

Registered Address

Elthorne Gate
64 High Street
Pinner
HA5 5QA

Registered Number

13735777 (England and Wales)
JERICHO PHARMA LIMITED
Balance Sheet as at
30 November 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Intangible assets373,97782,766
Tangible assets42,8681,481
76,84584,247
Current assets
Stocks524,80012,174
Debtors6104,78266,706
Cash at bank and on hand28,7207,598
158,30286,478
Creditors amounts falling due within one year7(234,636)(181,660)
Net current assets (liabilities)(76,334)(95,182)
Total assets less current liabilities511(10,935)
Net assets511(10,935)
Capital and reserves
Called up share capital300300
Profit and loss account211(11,235)
Shareholders' funds511(10,935)
The financial statements were approved and authorised for issue by the Board of Directors on 3 June 2024, and are signed on its behalf by:
FAHIM, Mohammed
Director
PATEL, Vimal
Director
SHARIF, Zahoor Ahmed
Director

Registered Company No. 13735777
JERICHO PHARMA LIMITED
Notes to the Financial Statements
for the year ended 30 November 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Fixtures and fittings25
Stocks and work in progress
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20232022
Average number of employees during the year12
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 December 2287,89387,893
At 30 November 2387,89387,893
Amortisation and impairment
At 01 December 225,1275,127
Charge for year8,7898,789
At 30 November 2313,91613,916
Net book value
At 30 November 2373,97773,977
At 30 November 2282,76682,766
4.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 December 221,734-1,734
Additions-2,6372,637
At 30 November 231,7342,6374,371
Depreciation and impairment
At 01 December 22253-253
Charge for year3718791,250
At 30 November 236248791,503
Net book value
At 30 November 231,1101,7582,868
At 30 November 221,481-1,481
5.Stocks

2023

2022

££
Finished goods24,80012,174
Total24,80012,174
6.Debtors: amounts due within one year

2023

2022

££
Trade debtors / trade receivables70,03029,815
Other debtors31,19033,766
Prepayments and accrued income3,5623,125
Total104,78266,706
7.Creditors: amounts due within one year

2023

2022

££
Trade creditors / trade payables46,60428,771
Taxation and social security2,605-
Payments received on account12,177-
Other creditors163,875152,889
Accrued liabilities and deferred income9,375-
Total234,636181,660
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.